Denosumab approved in US for male osteoporosis
This article was originally published in Scrip
Executive Summary
The US FDA has approved Amgen's Prolia (denosumab) for the additional indication of male osteoporosis, providing a new alternative to older drugs such as bisphosphonates in a condition affecting increasing numbers of men.